Phase II proof‐of‐concept study of atorvastatin in castration‐resistant prostate cancer
| العنوان: | Phase |
|---|---|
| المؤلفون: | Linda K. Rushworth, Carolyn Loveridge, Mark Salji, Martin MacLeod, Ernest Mui, David Sumpton, Matthew Neilson, Ann Hedley, Laura Alexander, Elaine McCartney, Rachana Patel, Jan Wallace, Christian Delles, Rob Jones, Hing Y. Leung |
| المصدر: | BJU International. 131:236-243 |
| بيانات النشر: | Wiley, 2022. |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | Urology |
| الوصف: | To test for evidence of statin-mediated effects in patients with castration-resistant prostate cancer (CRPC) as post-diagnosis use of statins in patients with prostate cancer is associated with favourable survival outcome.The SPECTRE trial was a 6-weeks-long proof-of-concept single-arm Phase II treatment trial, combining atorvastatin and androgen deprivation therapy in patients with CRPC (regardless of metastatic status), designed to test for evidence of statin-mediated effects in patients with CRPC. The primary study endpoint was the proportion of patients achieving a ≥50% drop from baseline in prostate-specific antigen (PSA) levels at any time over the 6-week period of atorvastatin medication (PSA response). Exploratory endpoints include PSA velocity and serum metabolites identified by mass spectrometry .At the scheduled interim analysis, one of 12 patients experienced a ≥50% drop in PSA levels (primary endpoint), with ≥2 patients satisfying the primary endpoint required for further recruitment. All 12 patients experienced substantial falls in serum cholesterol levels following statin treatment. While all patients had comparable pre-study PSA velocities, six of 12 patients showed decreased PSA velocities after statin treatment, suggestive of disease stabilization. Unbiased metabolomics analysis on serial weekly blood samples identified tryptophan to be the dominant metabolite associated with patient response to statin.Data from the SPECTRE study provide the first evidence of statin-mediated effects on CRPC and early sign of disease stabilization. Our data also highlight the possibility of altered tryptophan metabolism being associated with tumour response. |
| تدمد: | 1464-410X 1464-4096 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa4ae89b78b0833957586dd7957ea752 https://doi.org/10.1111/bju.15851 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....fa4ae89b78b0833957586dd7957ea752 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 1464410X 14644096 |
|---|